Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging Study of [89Zr]Zr-BI 765063 and [89Zr]Zr-BI 770371 in Patients Treated With Ezabenlimab
NCT05068102Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2022
- Primary completion
- Jan 2026
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 765063 and BI 770371 in head and neck squamous cell carcinoma (HNSCC), melanoma and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Relative change from baseline of peak Standardized Uptake Values (SUVs) of [89Zr]Zr-BI 765063 and Relative change from baseline of peak Standardized Uptake Values (SUVs) of [89Zr]Zr-BI 770371. Started Mar 2022; status: active, not recruiting.
02
Drugs
BI 765063BI 770371
03
Conditions
head and neck squamous cell carcinoma (HNSCC)melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05068102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05068102.